Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Legend Biotech ( (LEGN) ) has shared an announcement.
On April 14, 2026, Legend Biotech reported that CARVYKTI® generated approximately $597 million in net trade sales for the quarter ended March 31, 2026, based on figures supplied by collaboration partner Janssen. The company emphasized that these sales numbers are preliminary, subject to completion of its quarterly financial statements, and have not yet been audited or reviewed by its independent accountants, so the final revenue and profit contribution from CARVYKTI® could differ once full results are finalized.
The disclosure underscores the growing commercial traction of CARVYKTI® within the multiple myeloma market and highlights its importance to Legend Biotech’s financial performance. However, management cautioned that a range of industry risks, including clinical, regulatory, competitive and intellectual property uncertainties, could affect future results, signaling that investors should treat the latest sales data as an early indicator rather than a definitive measure of the therapy’s long-term contribution.
The most recent analyst rating on (LEGN) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
The score balances strong, confidence-boosting earnings-call guidance and accelerating CARVYKTI commercial traction against still-weak financial quality (net losses and negative free cash flow) and a technically weak price trend. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech is a biotechnology company focused on developing and commercializing cell therapies, notably in oncology. Its primary product, CARVYKTI®, is a CAR-T cell therapy for multiple myeloma, marketed through a collaboration and license agreement with Janssen, giving the company exposure to the fast-growing market for advanced cancer treatments.
Average Trading Volume: 2,124,503
Technical Sentiment Signal: Sell
Current Market Cap: $3.36B
Find detailed analytics on LEGN stock on TipRanks’ Stock Analysis page.